An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia An open-label randomized controlled study
Latest Information Update: 27 Apr 2021
Price :
$35 *
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- 27 Apr 2021 New trial record